HRS-5041

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Fudan University, Hansoh BioMedical R&D Company

Conditions

Advanced Prostate CancerProstate Cancer Metastatic Disease

Phase 1

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

RecruitingNCT05942001

Jiangsu HengRui Medicine Co., Ltd.Advanced Prostate Cancer

Start: 2023-08-03End: 2025-08-31Target: 100Updated: 2025-02-19

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

RecruitingNCT07115446

Hansoh BioMedical R&D CompanyAdvanced Prostate Cancer

Start: 2025-08-19End: 2028-12-31Target: 63Updated: 2025-12-05

Phase 2

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

Not yet recruitingNCT06738745

Fudan UniversityProstate Cancer Metastatic Disease

Start: 2024-12-31End: 2027-08-31Target: 90Updated: 2024-12-18